Zealand Pharma
ZEAL.CO Large CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Zealand Pharma en bref
Zealand Pharma (ZEAL.CO) is currently trading at 283,40 € with a market capitalization of 17,2 Md €. The trailing P/E ratio stands at 3.17x, with a forward P/E of 30.54x. The 52-week range spans from 233,50 € to 556,00 €; the current price is 49% below the yearly high. Year-over-year revenue growth stands at +325.0%. The net profit margin stands at 69.21%.
💰 Dividende
Zealand Pharma currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
14 analystes évaluent Zealand Pharma (ZEAL.CO) au consensus : Acheter. L'objectif de cours moyen est de 457,57 €, soit un potentiel de +61.46% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 300,00 € à 745,00 €.
Zealand Pharma : la thèse d'investissement en détail
Zealand Pharma (ZEAL.CO) operates in the Healthcare — specifically Biotechnology — and is headquartered in Denmark. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 325% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 99.99%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 56.16% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
Valorisation en contexte
The EV/EBITDA multiple of 0.9x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 61.46% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 325% sur un an
- Rentable avec une marge nette de 69.21%
- Rentabilité élevée des capitaux propres (56.16% ROE)
- Marge brute élevée de 99.99% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Actuellement jugée sous-évaluée
- Bilan solide avec faible endettement (D/E 2.86)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Zealand Pharma?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news